Trials / Active Not Recruiting
Active Not RecruitingNCT05277051
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remzistotug | Remzistotug will be administered. |
| DRUG | Dostarlimab | Dostarlimab will be administered. |
| DRUG | Belrestotug | Belrestotug will be administered. |
| DRUG | Nelistotug | Nelistotug will be administered. |
| DRUG | GSK5764227 | GSK5764227 will be administered. |
Timeline
- Start date
- 2022-03-22
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
- First posted
- 2022-03-14
- Last updated
- 2026-03-23
Locations
26 sites across 9 countries: United States, Australia, Canada, China, France, Japan, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05277051. Inclusion in this directory is not an endorsement.